Skip to main content
Equibles

SXTC · China SXT Pharmaceuticals, Inc.

Track SXTC — free

Use SXTC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SXTC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.41 -0.55 (-18.58%) At close · Oct 2
Rebalance outlook locked
Market Cap
$3.40M
Shares
1.32M
Volume · Oct 2 779.92K Avg daily vol (39 sessions) 1.37M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.41 Open$3.00 Day$1.94–3.09 52W close$0.05–300.00 Avg vol 30d725K Short int66K · 5.0% float · 1.0d Short vol32% DataJan 2020–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
5.0%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bearish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −93%
below
Price vs 50-day avg −14%
below
RSI (14) 46
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +10%
trailing
6-month return +77%
trailing
YTD return −99%
this year
Relative strength +65%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $3 › 200d $35 — 200d above 50d
Institutional flow Distributing
-25% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.96% of float · ▲ +251.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
3 holders — near 3-yr low, contrarian setup
Squeeze score 57
elevated · 0–100
Fundamentals
Weak
Revenue growth −2%
Y/Y
Gross margin 13%
contracting
EPS growth +97%
Y/Y
Free cash flow $-4.0M
Balance sheet $27.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 9777%
annualized · 1-yr
Max drawdown −100%
past year
ATR 21.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−93% Bearish
Price vs 50-day avg
−14% Bearish
RSI (14)
46 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $35 — 200d above 50d
Institutional flow Distributing
-25% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.96% of float · ▲ +251.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
3 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $2 · 1% Range high $300
vs 200-day avg -93% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SXTC
China SXT Pharmaceuticals, Inc.
this stock
$3.40M — -2.2% — 5.0%
TAK
Takeda Pharmaceutical Co Ltd
 $60.23B +14.6% — — 0.1%
GALDY
Galderma Group AG/ADR
 $46.00B -6.5% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $45.67B +26.7% +4.3% 64.3 2.7%
HLN
Haleon plc
 $40.72B -13.0% — — 0.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
3
% held
0.0%
Net QoQ
-977 sh
Top holder
ROYAL BANK OF CANADA
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
65.5K
Days to cover
1.0d
Change
+46.9K sh
View
Short Volume
Short vol %
32%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
56.6K
Value
$145.0K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
52.9%
Week of
Aug 24, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.9M
Net income (FY)
$-6.2M
EPS diluted
$-730.40
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 28, 2026
This year
8
View

Performance

5D 20D 120D MTD YTD
SXTC -6.2% +9.6% +77.2% -19.9% -99.0%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -6.0% +10.0% +65.0% -20.9% -111.9%
Key facts CIK 1723980 CUSIP G2161P173